Jacek Golanski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jacek Golanski has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Cezary Watala
Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland
17 shared publications- Marcin Rozalski
Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland
16 shared publications - Boguslawa Luzak
Department of Hemostasis and Hemostatic Disorders, Medical University of Lodz, 92-215 Lodz, Poland
12 shared publications - Cezary Watala
Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland
8 shared publications - Cezary Watala
Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland
8 shared publications Leszek Markuszewski
6 shared publications
Latest Publications
- 2 November 2026
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 62 (4) , 211-237
2026. Guidelines of the Working Group of thePolish Society of Laboratory Diagnostics andCollege of Laboratory Medicine for Diagnosticsof Haemostasis – pre-analytical errors inlaboratory tests in haemostasis
Diagnostic and therapeutic decisions made by physicians should be based on scientific evidence and reliable laboratory test results. Therefore, laboratories ensure the highest quality of results, relying on standardization and a quality management system for laboratory tests, in order to eliminate errors and reduce false results.However, a number of international and national reports indicate that pre-analytic errors, often committed outside the control of the laboratory, account for a significant proportion of the total number of errors and may account for up to about 70% of the causes of abnormalities in laboratory tests in haemostasis. This review identifies pre-analytic errors in haemostasis system testing, their sources and proposes ways to implement control measures to improve the quality of laboratory tests in the coagulation system. The document is based on the latest literature analyses from the last decade and may be useful for laboratory diagnosticians, doctors or medical professionals involved in the patient’s preparation, transport, analysis of blood samples and interpretation of results in haemostasis.
- 2 November 2026
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 62 (4) , 211-237
2026. Guidelines of the Working Group of thePolish Society of Laboratory Diagnostics andCollege of Laboratory Medicine for Diagnosticsof Haemostasis – pre-analytical errors inlaboratory tests in haemostasis
Diagnostic and therapeutic decisions made by physicians should be based on scientific evidence and reliable laboratory test results. Therefore, laboratories ensure the highest quality of results, relying on standardization and a quality management system for laboratory tests, in order to eliminate errors and reduce false results.However, a number of international and national reports indicate that pre-analytic errors, often committed outside the control of the laboratory, account for a significant proportion of the total number of errors and may account for up to about 70% of the causes of abnormalities in laboratory tests in haemostasis. This review identifies pre-analytic errors in haemostasis system testing, their sources and proposes ways to implement control measures to improve the quality of laboratory tests in the coagulation system. The document is based on the latest literature analyses from the last decade and may be useful for laboratory diagnosticians, doctors or medical professionals involved in the patient’s preparation, transport, analysis of blood samples and interpretation of results in haemostasis.
- 30 July 2026
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 62 (3) , 121-143
2026 Guidelines of the Working Group of the Polish Society of Laboratory Diagnostics for Hemostasis Diagnostics and the College of Laboratory Medicine on the basic panel of hemostasis tests as part of the organization of laboratory hemostasis diagnostics – interpretation of results, pitfalls, and clinical application in diagnostic practice
The basic haemostasis testing panel is the principal first-line laboratory assessment in patients with bleeding, suspected multifactorial coagulopathy, venous thromboembolism, disseminated intravascular coagulation, liver disease, complications of anticoagulant therapy, and emergency conditions requiring rapid evaluation of bleeding or thrombotic risk. Its core components include platelet count, prothrombin time, usually reported together with the international normalized ratio, activated partial thromboplastin time, fibrinogen measured using the Clauss method, and D-dimer concentration. In many laboratories, thrombin time provides complementary information, while reptilase time may be useful in selected clinical situations.The basic panel should not be regarded solely as a set of screening assays. In a modern model of laboratory haemostasis diagnostics, it functions as a local decision-making node. It enables rapid identification of abnormalities, assessment of clinical urgency, recognition of preanalytical errors, planning of further investigations, and determination of whether the patient or the sample should be referred to a specialist laboratory.The diagnostic value of the panel depends not only on analytical performance, but also on the organization of the entire total testing process. This includes sample collection and transport, preparation of platelet-poor plasma, time from collection to analysis, drug-related interference, quality control, reporting of results, use of interpretative comments, and clearly defined pathways for further testing. The greatest diagnostic value is achieved through integrated interpretation of all parameters rather than isolated assessment of individual results.Each result pattern should be evaluated with consideration of sample quality, the blood-to-citrate ratio, haematocrit, plasma preparation, time to analysis, anticoagulant and antiplatelet therapy, and the limitations of the specific analyser–reagent system. Particular attention should be paid to differentiating coagulation factor deficiency from the presence of an inhibitor, which often requires a plasma mixing test, and to distinguishing genuine haemostatic abnormalities from those caused by preanalytical errors, heparin contamination, direct oral anticoagulant interference, or inappropriate interpretation of D-dimer concentration.
- 30 July 2026
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 62 (3) , 121-143
2026 Guidelines of the Working Group of the Polish Society of Laboratory Diagnostics for Hemostasis Diagnostics and the College of Laboratory Medicine on the basic panel of hemostasis tests as part of the organization of laboratory hemostasis diagnostics – interpretation of results, pitfalls, and clinical application in diagnostic practice
The basic haemostasis testing panel is the principal first-line laboratory assessment in patients with bleeding, suspected multifactorial coagulopathy, venous thromboembolism, disseminated intravascular coagulation, liver disease, complications of anticoagulant therapy, and emergency conditions requiring rapid evaluation of bleeding or thrombotic risk. Its core components include platelet count, prothrombin time, usually reported together with the international normalized ratio, activated partial thromboplastin time, fibrinogen measured using the Clauss method, and D-dimer concentration. In many laboratories, thrombin time provides complementary information, while reptilase time may be useful in selected clinical situations.The basic panel should not be regarded solely as a set of screening assays. In a modern model of laboratory haemostasis diagnostics, it functions as a local decision-making node. It enables rapid identification of abnormalities, assessment of clinical urgency, recognition of preanalytical errors, planning of further investigations, and determination of whether the patient or the sample should be referred to a specialist laboratory.The diagnostic value of the panel depends not only on analytical performance, but also on the organization of the entire total testing process. This includes sample collection and transport, preparation of platelet-poor plasma, time from collection to analysis, drug-related interference, quality control, reporting of results, use of interpretative comments, and clearly defined pathways for further testing. The greatest diagnostic value is achieved through integrated interpretation of all parameters rather than isolated assessment of individual results.Each result pattern should be evaluated with consideration of sample quality, the blood-to-citrate ratio, haematocrit, plasma preparation, time to analysis, anticoagulant and antiplatelet therapy, and the limitations of the specific analyser–reagent system. Particular attention should be paid to differentiating coagulation factor deficiency from the presence of an inhibitor, which often requires a plasma mixing test, and to distinguishing genuine haemostatic abnormalities from those caused by preanalytical errors, heparin contamination, direct oral anticoagulant interference, or inappropriate interpretation of D-dimer concentration.
- 25 June 2026
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 62 (2) , 1-10
Organization of Laboratory Hemostasis Diagnostics in Polandand Worldwide: A Functional Model Proposal as a StartingPoint for National Guidelines
The organization of laboratory hemostasis diagnostics is undergoing substantialtransformation. The traditional model of local, partly self-sufficient laboratoriesis being replaced by a functional model based on levels of competence,consolidation of specialized testing, hub-and-spoke systems, supervised point-of-care testing, and harmonization of preanalytical, analytical, and postanalyticalprocedures. The aim of this discussion paper is to initiate a professional debateon the Polish model of laboratory hemostasis diagnostics as a prerequisite for thedevelopment of future guideline-based documents. The manuscript highlightsthe need to link local and specialist laboratories with the clinical network ofcenters managing bleeding disorders, thromboembolic disease, inherited andacquired thrombophilia, and antiphospholipid syndrome. It emphasizes thatPoland has elements of an organized clinical network, particularly in the field ofhemophilia and related bleeding disorders, but lacks an equally explicit nationalnetwork of hemostasis laboratories. A two-level model is proposed, consistingof a local level responsible for urgent and basic testing and a specialist levelresponsible for extended diagnostics, expert interpretation, consultation, andquality supervision. Agreement on such a model should precede the preparationof detailed diagnostic algorithms, sample referral rules, interpretative comments,and recommendations for point-of-care testing.
- 25 June 2026
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 62 (2) , 1-10
Organization of Laboratory Hemostasis Diagnostics in Polandand Worldwide: A Functional Model Proposal as a StartingPoint for National Guidelines
The organization of laboratory hemostasis diagnostics is undergoing substantialtransformation. The traditional model of local, partly self-sufficient laboratoriesis being replaced by a functional model based on levels of competence,consolidation of specialized testing, hub-and-spoke systems, supervised point-of-care testing, and harmonization of preanalytical, analytical, and postanalyticalprocedures. The aim of this discussion paper is to initiate a professional debateon the Polish model of laboratory hemostasis diagnostics as a prerequisite for thedevelopment of future guideline-based documents. The manuscript highlightsthe need to link local and specialist laboratories with the clinical network ofcenters managing bleeding disorders, thromboembolic disease, inherited andacquired thrombophilia, and antiphospholipid syndrome. It emphasizes thatPoland has elements of an organized clinical network, particularly in the field ofhemophilia and related bleeding disorders, but lacks an equally explicit nationalnetwork of hemostasis laboratories. A two-level model is proposed, consistingof a local level responsible for urgent and basic testing and a specialist levelresponsible for extended diagnostics, expert interpretation, consultation, andquality supervision. Agreement on such a model should precede the preparationof detailed diagnostic algorithms, sample referral rules, interpretative comments,and recommendations for point-of-care testing.
- Open Access
- 23 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 821
A Practical Approach to Platelet Phenotype Profiling Using Microplate Aggregometry
Background/Objectives: Blood platelets exhibit substantial functional heterogeneity, yet no established principles exist for distinguishing their subpopulations. The present study proposes a methodology for the evaluation of platelet reactivity and inhibitor sensitivity, with the aim of facilitating the expeditious identification of platelet phenotypes under standard laboratory conditions. Methods: The phenotyping of healthy subjects was based on the study of platelet aggregation in response to agonists and inhibitors of P2Y12, PAR-1 and GPVI receptors. The classification of variants was conducted on the basis of the similarities and differences in EC50/IC50 values obtained for individual ligands. Subsequently, the values were subjected to two- and six-variable cluster analyses. Results: Two major clusters (variants) were identified with consistent reliability across the range of analytical strategies employed. Cluster 1 comprised individuals with low EC50 values and moderate to high IC50 values, indicating high agonist responsiveness and relatively low inhibitor sensitivity. Conversely, cluster 2 exhibited the inverse pattern, characterised by moderate to high EC50 values and moderate to low IC50 values. Cluster 1 constituted a significant proportion of individuals (29–78%, depending on the analysis). The study did not identify a “low responder group”. Conclusions: The proposed methodology is distinguished by two features: its flexibility and its accessibility. These characteristics enable the identification of any platelet phenotype associated with selected signalling pathway(s). The application of this approach has the potential to facilitate the identification of individuals at elevated cardiovascular risk, thereby informing personalised antiplatelet therapy in the context of primary prevention.
- 23 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 821
Open AccessA Practical Approach to Platelet Phenotype Profiling Using Microplate Aggregometry
Background/Objectives: Blood platelets exhibit substantial functional heterogeneity, yet no established principles exist for distinguishing their subpopulations. The present study proposes a methodology for the evaluation of platelet reactivity and inhibitor sensitivity, with the aim of facilitating the expeditious identification of platelet phenotypes under standard laboratory conditions. Methods: The phenotyping of healthy subjects was based on the study of platelet aggregation in response to agonists and inhibitors of P2Y12, PAR-1 and GPVI receptors. The classification of variants was conducted on the basis of the similarities and differences in EC50/IC50 values obtained for individual ligands. Subsequently, the values were subjected to two- and six-variable cluster analyses. Results: Two major clusters (variants) were identified with consistent reliability across the range of analytical strategies employed. Cluster 1 comprised individuals with low EC50 values and moderate to high IC50 values, indicating high agonist responsiveness and relatively low inhibitor sensitivity. Conversely, cluster 2 exhibited the inverse pattern, characterised by moderate to high EC50 values and moderate to low IC50 values. Cluster 1 constituted a significant proportion of individuals (29–78%, depending on the analysis). The study did not identify a “low responder group”. Conclusions: The proposed methodology is distinguished by two features: its flexibility and its accessibility. These characteristics enable the identification of any platelet phenotype associated with selected signalling pathway(s). The application of this approach has the potential to facilitate the identification of individuals at elevated cardiovascular risk, thereby informing personalised antiplatelet therapy in the context of primary prevention.
- 27 March 2026
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 62 (1) , 1-26
2026 Guidelines of the Polish Society ofLaboratory Diagnostics Working Groupon Hemostasis Diagnostics for theassessment of platelet parameters andthe verification of thrombocytopenia inautomated blood counts
The aim of this paper is to update and expand previously published guidelines in “Diagnostyka Laboratoryjna” by summarising contemporary methods for platelet count (PLT) measurement and platelet morphology assessment, including impedance, optical, fluorescent, hybrid, and digital technologies. The document discusses analytical artefacts (including EDTA-dependent pseudothrombocytopenia) and key pre-analytical factors, compares reference intervals (RI) for the Polish population and selected countries with attention to paediatric and geriatric subgroups and sex, and proposes a practical algorithm for verification of thrombocytopenia supported by digital image analysis. The scoping review covered publications from 2000–2026 retrieved from PubMed, Google Scholar, SciSpace, Web of Science, Scopus, and the "Diagnostyka Laboratoryjna" archive, prioritising validation studies of PLT-F/PLT-O/PLT-H, evidence on immature platelet fraction (IPF), and studies evaluating digital morphology systems (e.g., DI-60, MC-80/MC-100i). Overall, fluorescent methods (PLT-F) show the highest agreement with reference procedures in low PLT ranges. Implementation of reflex rules combining alternative measurement principles, smear review (manual or digital), and anticoagulant change (e.g., MgSO₄/CTAD) in suspected EDTA-PTCP reduces the risk of reporting erroneous results. Reference intervals in Poland for adults are 150-400 × 10⁹/L; paediatric and geriatric data confirm dependencies on age and sex. Digital image analysis increases the detection of platelet clumps, standardises smear review, and shortens turnaround time (TAT). The implementation of reflex rules based on PLT-F/PLT-O/PLT-H and digital smear assessment limits the risk of errors. Interpretation of results should consider age, sex, and population; digital morphology (DI-60, MC-80/MC-100i) should be an integral part of the verification pathway.
- 27 March 2026
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 62 (1) , 1-26
2026 Guidelines of the Polish Society ofLaboratory Diagnostics Working Groupon Hemostasis Diagnostics for theassessment of platelet parameters andthe verification of thrombocytopenia inautomated blood counts
The aim of this paper is to update and expand previously published guidelines in “Diagnostyka Laboratoryjna” by summarising contemporary methods for platelet count (PLT) measurement and platelet morphology assessment, including impedance, optical, fluorescent, hybrid, and digital technologies. The document discusses analytical artefacts (including EDTA-dependent pseudothrombocytopenia) and key pre-analytical factors, compares reference intervals (RI) for the Polish population and selected countries with attention to paediatric and geriatric subgroups and sex, and proposes a practical algorithm for verification of thrombocytopenia supported by digital image analysis. The scoping review covered publications from 2000–2026 retrieved from PubMed, Google Scholar, SciSpace, Web of Science, Scopus, and the "Diagnostyka Laboratoryjna" archive, prioritising validation studies of PLT-F/PLT-O/PLT-H, evidence on immature platelet fraction (IPF), and studies evaluating digital morphology systems (e.g., DI-60, MC-80/MC-100i). Overall, fluorescent methods (PLT-F) show the highest agreement with reference procedures in low PLT ranges. Implementation of reflex rules combining alternative measurement principles, smear review (manual or digital), and anticoagulant change (e.g., MgSO₄/CTAD) in suspected EDTA-PTCP reduces the risk of reporting erroneous results. Reference intervals in Poland for adults are 150-400 × 10⁹/L; paediatric and geriatric data confirm dependencies on age and sex. Digital image analysis increases the detection of platelet clumps, standardises smear review, and shortens turnaround time (TAT). The implementation of reflex rules based on PLT-F/PLT-O/PLT-H and digital smear assessment limits the risk of errors. Interpretation of results should consider age, sex, and population; digital morphology (DI-60, MC-80/MC-100i) should be an integral part of the verification pathway.
- Open Access
- 24 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (1) , 49
Complex Pattern of Platelet Activation/Reactivity After SARS-CoV-2 Infection
COVID-19 and post-COVID (long COVID) are associated with thromboembolic complications; however, it is still not clear whether platelets play a leading role in this phenomenon. The platelet hyperreactivity could result from the direct interaction between platelets and viral elements or the response to inflammatory and prothrombotic factors released from blood and vessel cells following infection. The existing literature does not provide clear-cut answers, as the results determining platelet status vary according to methodology. Elevated levels of soluble markers of platelet activation (P selectin, PF4), increased platelet aggregates, and platelet-derived microparticles suggest the activation of platelets circulating in the bloodstream of COVID-19 patients. Similarly, platelets isolated from COVID-19 patients demonstrate increased reactivity in response to collagen, thrombin, and ADP. By contrast, an analysis of whole blood from COVID-19 patients indicates the reduced activation of the fibrinogen receptor. Similarly, some in vitro studies report potential targets for SARS-CoV-2 in platelets, whereas others do not indicate any direct effect of the virus on platelets. The aim of this work is to review and evaluate the reliability of the methodology for testing platelet function after contact with SARS-CoV-2. Despite the diversity of methods yielding varying results and the influence of plasma components or blood cells, it can be concluded that platelets play an important role in the development of thrombotic complications after exposure to SARS-CoV-2.
- 24 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (1) , 49
Open AccessComplex Pattern of Platelet Activation/Reactivity After SARS-CoV-2 Infection
COVID-19 and post-COVID (long COVID) are associated with thromboembolic complications; however, it is still not clear whether platelets play a leading role in this phenomenon. The platelet hyperreactivity could result from the direct interaction between platelets and viral elements or the response to inflammatory and prothrombotic factors released from blood and vessel cells following infection. The existing literature does not provide clear-cut answers, as the results determining platelet status vary according to methodology. Elevated levels of soluble markers of platelet activation (P selectin, PF4), increased platelet aggregates, and platelet-derived microparticles suggest the activation of platelets circulating in the bloodstream of COVID-19 patients. Similarly, platelets isolated from COVID-19 patients demonstrate increased reactivity in response to collagen, thrombin, and ADP. By contrast, an analysis of whole blood from COVID-19 patients indicates the reduced activation of the fibrinogen receptor. Similarly, some in vitro studies report potential targets for SARS-CoV-2 in platelets, whereas others do not indicate any direct effect of the virus on platelets. The aim of this work is to review and evaluate the reliability of the methodology for testing platelet function after contact with SARS-CoV-2. Despite the diversity of methods yielding varying results and the influence of plasma components or blood cells, it can be concluded that platelets play an important role in the development of thrombotic complications after exposure to SARS-CoV-2.
- 1 January 2024
- Published by Polskie Towarzystwo Technologow Zywnosci Wydawnictwo Naukowe PTTZ in Zywnosc Nauka Technologia Jakosc/Food Science Technology Quality
- Vol. 31 (2) , 120-140
ZNACZENIE WYBRANYCH SKŁADNIKÓW ŻYWNOŚCI POCHODZENIA ROŚLINNEGO HAMUJĄCYCH FUNKCJE PŁYTEK KRWI W PROFILAKTYCE PIERWOTNEJ CHORÓB SERCOWO-NACZYNIOWYCH
Background. Cardiovascular diseases (CVDs), which are responsible for the largest number of deaths in the world, are caused by modifiable factors, including improper nutrition, high levels of LDL cholesterol or triglycerides in blood serum, as well as inflammation or increased platelet activity. The results of many scientific studies, including meta-analyses from randomized controlled trials, indicate that food rich in (poly)phenols or unsaturated fatty acids significantly reduces the risk of CVD by normalizing blood lipid levels, reducing platelet activity, and having anti-inflammatory and antioxidant effects. The combination of both active ingredients is the Mediterranean diet, based on a high consumption of olive oil and vegetables, and the ingredients of this diet are included in European health claims (tomato extract has antiplatelet properties; olive (poly)phenols have antioxidant and anti-inflammatory properties). Results and conclusions. The paper describes the most important (poly)phenolic compounds and fatty acids contained in vegetable oils with antiplatelet properties and describes publications proving their effect in model systems (in vitro). Due to the limited bioavailability of plant-derived compounds with antiplatelet properties, there is still no satisfactory evidence from clinical trials that supplementation with preparations containing (poly)phenols and/or unsaturated fatty acids is beneficial in the primary prevention of cardiovascular diseases, the focus should be on developing foods that combine the health-promoting effects of olive oil and processed tomatoes. Research into the use of such designed functional foods showing antiplatelet effects in the prevention of cardiovascular diseases should be considered.
- 1 January 2024
- Published by Polskie Towarzystwo Technologow Zywnosci Wydawnictwo Naukowe PTTZ in Zywnosc Nauka Technologia Jakosc/Food Science Technology Quality
- Vol. 31 (2) , 120-140
ZNACZENIE WYBRANYCH SKŁADNIKÓW ŻYWNOŚCI POCHODZENIA ROŚLINNEGO HAMUJĄCYCH FUNKCJE PŁYTEK KRWI W PROFILAKTYCE PIERWOTNEJ CHORÓB SERCOWO-NACZYNIOWYCH
Background. Cardiovascular diseases (CVDs), which are responsible for the largest number of deaths in the world, are caused by modifiable factors, including improper nutrition, high levels of LDL cholesterol or triglycerides in blood serum, as well as inflammation or increased platelet activity. The results of many scientific studies, including meta-analyses from randomized controlled trials, indicate that food rich in (poly)phenols or unsaturated fatty acids significantly reduces the risk of CVD by normalizing blood lipid levels, reducing platelet activity, and having anti-inflammatory and antioxidant effects. The combination of both active ingredients is the Mediterranean diet, based on a high consumption of olive oil and vegetables, and the ingredients of this diet are included in European health claims (tomato extract has antiplatelet properties; olive (poly)phenols have antioxidant and anti-inflammatory properties). Results and conclusions. The paper describes the most important (poly)phenolic compounds and fatty acids contained in vegetable oils with antiplatelet properties and describes publications proving their effect in model systems (in vitro). Due to the limited bioavailability of plant-derived compounds with antiplatelet properties, there is still no satisfactory evidence from clinical trials that supplementation with preparations containing (poly)phenols and/or unsaturated fatty acids is beneficial in the primary prevention of cardiovascular diseases, the focus should be on developing foods that combine the health-promoting effects of olive oil and processed tomatoes. Research into the use of such designed functional foods showing antiplatelet effects in the prevention of cardiovascular diseases should be considered.
- 22 December 2023
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 59 (4) , 1-18
The Coagulology Section of the Polish Societyof Laboratory Diagnostics recommendations on the plateletreactivity test. 2023
- 22 December 2023
- Published by Index Copernicus in Diagnostyka Laboratoryjna
- Vol. 59 (4) , 1-18
The Coagulology Section of the Polish Societyof Laboratory Diagnostics recommendations on the plateletreactivity test. 2023
- Open Access
- 5 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14914
Platelets as Potential Non-Traditional Cardiovascular Risk Factor—Analysis Performed in Healthy Donors
Abnormal lipid profile, increased glucose level, and elevated body weight are traditional cardiometabolic risk factors; however, the role of platelets in the development of cardiovascular disease (CVD) is increasingly being highlighted. The aim of this study was to select platelet-related parameters (non-genetic molecular and routine laboratory measurements) that may be associated with increased cardiovascular risk among healthy populations. We evaluated the level of platelet indices, platelet-based inflammatory markers, platelet reactivity parameters, and platelet reactive oxygen species (ROS) generation in relation to selected cardiometabolic risk factors. We noted the association between total cholesterol and LDL cholesterol with platelet aggregation and platelet ROS generation. We found the relationship between triglycerides, glucose, and body mass index with the relatively new multi-inflammatory indices (MII-1 and MII-3). Moreover, we noticed that the mean platelet volume-to-lymphocyte ratio in healthy subjects is not a good source of information about platelets and inflammation. We also highlighted that platelet-to-HDL-cholesterol ratio may be a promising prognostic cardiometabolic indicator. The association between platelet-related (especially molecular) and cardiometabolic parameters requires further research. However, the goal of this study was to shed light on the consideration of platelets as a non-traditional cardiovascular risk factor and a crucial element in identifying individuals at high-risk of developing CVD in the future.
- 5 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14914
Open AccessPlatelets as Potential Non-Traditional Cardiovascular Risk Factor—Analysis Performed in Healthy Donors
Abnormal lipid profile, increased glucose level, and elevated body weight are traditional cardiometabolic risk factors; however, the role of platelets in the development of cardiovascular disease (CVD) is increasingly being highlighted. The aim of this study was to select platelet-related parameters (non-genetic molecular and routine laboratory measurements) that may be associated with increased cardiovascular risk among healthy populations. We evaluated the level of platelet indices, platelet-based inflammatory markers, platelet reactivity parameters, and platelet reactive oxygen species (ROS) generation in relation to selected cardiometabolic risk factors. We noted the association between total cholesterol and LDL cholesterol with platelet aggregation and platelet ROS generation. We found the relationship between triglycerides, glucose, and body mass index with the relatively new multi-inflammatory indices (MII-1 and MII-3). Moreover, we noticed that the mean platelet volume-to-lymphocyte ratio in healthy subjects is not a good source of information about platelets and inflammation. We also highlighted that platelet-to-HDL-cholesterol ratio may be a promising prognostic cardiometabolic indicator. The association between platelet-related (especially molecular) and cardiometabolic parameters requires further research. However, the goal of this study was to shed light on the consideration of platelets as a non-traditional cardiovascular risk factor and a crucial element in identifying individuals at high-risk of developing CVD in the future.
- Open Access
The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3 polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs are well known, but the effect of resolvin E1 on platelets via the collagen receptors is extremely poorly reported. We investigated the effect of resolvin E1 on collagen-induced platelet aggregation, activation, and reactivity, and also platelet membrane fluidity. The ultimate and statistically significant results showed that resolvin E1 may inhibit platelet reactivity due to the reduction of collagen-induced platelet aggregation in platelet-rich plasma and isolated platelets, but not in whole blood. Also, resolvin E1 significantly reduced P-selectin exposure on collagen-stimulated platelets. Moreover, we demonstrated that resolvin E1 can maintain platelet membrane structure (without increasing membrane fluidity). The association between platelet reactivity and membrane fluidity, including resolvin E1 and collagen receptors requires further research. However, the goal of this study was to shed light on the molecular mechanisms behind the anti-aggregative effects of resolvin E1 on platelets, which are still not fully clarified. We also indicate an innovative research direction focused on further analysis and then use of omega-3 PUFAs metabolites as antiplatelet compounds for future applications in the treatment and prevention of cardiovascular diseases.
Open AccessThe Anti-Aggregative Potential of Resolvin E1 on Human Platelets
Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3 polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs are well known, but the effect of resolvin E1 on platelets via the collagen receptors is extremely poorly reported. We investigated the effect of resolvin E1 on collagen-induced platelet aggregation, activation, and reactivity, and also platelet membrane fluidity. The ultimate and statistically significant results showed that resolvin E1 may inhibit platelet reactivity due to the reduction of collagen-induced platelet aggregation in platelet-rich plasma and isolated platelets, but not in whole blood. Also, resolvin E1 significantly reduced P-selectin exposure on collagen-stimulated platelets. Moreover, we demonstrated that resolvin E1 can maintain platelet membrane structure (without increasing membrane fluidity). The association between platelet reactivity and membrane fluidity, including resolvin E1 and collagen receptors requires further research. However, the goal of this study was to shed light on the molecular mechanisms behind the anti-aggregative effects of resolvin E1 on platelets, which are still not fully clarified. We also indicate an innovative research direction focused on further analysis and then use of omega-3 PUFAs metabolites as antiplatelet compounds for future applications in the treatment and prevention of cardiovascular diseases.